Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Patrick Schöffski
Management of Soft Tissue and Visceral Leiomyosarcomas
1Department of Medical Oncology, Sarcoma and Bone Tumors Reference Center, A.C.Camargo Cancer Center, São Paulo, Brazil 2Sarcoma Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada 3Department of Surgery, Mount Sinai Hospital, Sinai Health Systems, Toronto, Ontario, Canada 4National Leiomyosarcoma Foundation (NLMSF), Denver, Colorado 5Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine and Winship Cancer...
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors
|
Abstract Chimeric antigen receptor (CAR) T cell therapy for solid tumors is constrained by the scarcity of safe, uniformly expressed cell-surface targets. Here we identify glycoprotein NMB (GPNMB)—an MiT/TFE-family fusion-driven protein—as being highly, homogeneously and stably expressed in primary and relapsed alveolar soft-part sarcoma (ASPS) and translocation renal cell carcinoma.
By Franz J. Zemp, Hyojin Song, Taye Louie, Hongrui Liu, Yeon Ok Suh, Edna Ayerim Mandujano-Tinoco, Nicolas Collao, Joanna Pyczek, Kristofor K. Ellestad, Cini M. John, Laura K. Mah, Jahanara Rajwani, Danyel Evseev, Madison Turk, Sacha Benaoudia, Jonathan Alex, Victor Naumenko, Varsha Thoppey Manoharan, Harmony Smith, Aaron Gillmor, Hayley M. Todesco, Bo-Young Ahn, Colleen Anderson, Saif Sikdar, Tarek A. Bismar, Daniel Heng, Keith Lawson, W. Marston Linehan, Haley Pedersen, Paul Gordon, John McIntyre Verified, john Mcintyre, John MacGregor, Livia Garzia, Kathy Brodeur-Robb, Travis Ogilvie, Patrick Schöffski, Agnieszka Wozniak, Robert Holt, John Bell, Donna L. Senger, Victor A Lewis, Michael J. Monument, Omar Khan, Lou Baudrier, Pierre Billon, Vincent Gabriel, Jeff Biernaskie, Kiril Trpkov, Kevin Hay Verified, Jennifer Chan, Ramy R. Saleh, Jan Henning, Mona Shafey, A. Sorana Morrissy, Douglas J. Mahoney, Zackariah Breckenridge, Gurveer S. Gill, Kiran Narta, Louisa Guignard, Jada Curry, Jethro Langley, Mobina Kazemi Mehrabadi, Geneece N. Y. Gilbert, Ted B. Verhey, Katalin Osz, Ana Bogossian, Shahrbano Rukunuddin, Lisa DiFrancesco, Kyle Potts, Jennifer Quizi, Nicole L. Prokopishyn
|
Nature
Verified
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma
Keywords NIZ985 heterodimeric IL-15 Spartalizumab Tislelizumab Phase I/Ib clinical trial Solid tumors Get full text access Log in, subscribe or purchase for full access. Data availability statement Data are available on reasonable request. Novartis will not provide access to patient-level data, if there is a reasonable likelihood that individual patients could be reidentified.
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
A Phase 2, Multicenter, Open-Label Study of Anti-Lag-3 Ieramilimab in Combination With Anti-Pd-1 Spartalizumab in Patients With Advanced Solid Malignancies
Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment in patients with selected advanced (locally advanced or metastatic) solid malignancies.
Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates
This content is only available via PDF. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS | Future Oncology
Future OncologyAhead of Print Clinical Trial ProtocolOpen Access Abstract Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive liposarcoma associated with poor prognosis. First-line treatment for advanced/metastatic DDLPS is systemic chemotherapy, but efficacy is poor and toxicities substantial. Most DDLPS tumors have amplification of the MDM2 gene, which encodes a negative regulator of the p53 suppressor protein.
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-
Highlights • More effective treatment regimens are needed for inoperable, metastatic soft tissue sarcomas (STSs). • Current treatment outcomes with second-line chemotherapy are unsatisfactory. • EORTC-1506-STBSG (second-line nintedanib versus ifosfamide) was stopped for futility. • The median progression-free survival of second-line nintedanib and ifosfamide was 2.5 and 4.4 months, respectively. • In non-selected, advanced STSs, further exploration of nintedanib is not warranted.
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
Abstract Background This open-label, phase 1 trial (NCT02316197) aimed to determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of peposertib (formerly M3814), a DNA-dependent protein kinase (DNA-PK) inhibitor in patients with advanced solid tumours. Secondary/exploratory objectives included safety/tolerability, pharmacokinetic/pharmacodynamic profiles and clinical activity.
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Summary Background Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. In this study, we report the clinical activity and safety of tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma.
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study | Journal of Clinical Oncology
Viktor Grünwald, MD1,2; Annika Karch, MSc3; Markus Schuler, MD4; Patrick Schöffski, MD5; Hans-Georg Kopp, MD6; Sebastian Bauer, MD7; Bernd Kasper, MD, PhD8; Lars H.
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Summary Background Targeting of KIT and PDGFRA with imatinib revolutionised treatment in gastrointestinal stromal tumour; however, PDGFRA Asp842Val (D842V)-mutated gastrointestinal stromal tumour is highly resistant to tyrosine kinase inhibitors.
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II tri
Highlights • This is the first disease-specific trial of cabozantinib in the treatment of gastrointestinal stromal tumour. • The primary end-point was met (24/41 of patients were progression-free at week 12). • Cabozantinib provided clinical benefit (partial response + stable disease: 82·0%, 95% confidence interval [CI] 69·0–91·0%). • The median overall survival was 18·2 months (95% CI 14·3–22·3).
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
Abstract Background This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma. Methods Patients ≥18 years old with advanced liposarcoma or leiomyosarcoma, ECOG PS ≤2, and ≥2 prior treatment regimens were randomly assigned (1:1) to eribulin mesylate (1.4 mg/m² intravenously on day 1 and day 8) or dacarbazine (either 850, 1000, or 1200 mg/m² intravenously) every 21 days until disease progression.
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
Publication HistoryPublished online: August 20, 2018Accepted: August 17, 2018; Received in revised form: August 14, 2018; Received: April 11, 2018;
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prosp
We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK).
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial
Publication HistoryPublished online: March 19, 2018Accepted: February 5, 2018; Received in revised form: January 22, 2018; Received: December 1, 2017;
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with
Publication HistoryPublished online: November 14, 2017Accepted: October 7, 2017; Received in revised form: September 29, 2017; Received: July 4, 2017;
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
The goal of this RDT was to use the multi-tumour design as a screening tool to identify up to two tumour-specific cohorts that could be expanded to provide a sufficient number of patients with SD during the lead-in stage for generation of clinically meaningful PFS results during the randomised stage.The study accrued within the estimated timelines. During the lead-in stage, cabozantinib demonstrated preliminary clinical activity in multiple tumour types.
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours - European Journal of Cancer
Publication HistoryPublished online: October 19, 2017Accepted: September 14, 2017; Received: September 1, 2017;
PS-2Phase (ph) 3 study of eribulin (ERI) vs dacarbazine (DTIC) in leiomyosarcoma (LMS) and liposarcoma (LPS) patients (pts)
PS-2Phase (ph) 3 study of eribulin (ERI) vs dacarbazine (DTIC) in leiomyosarcoma (LMS) and liposarcoma (LPS) patients (pts) Patrick Schöffski1, Edwin Choy2, Axel Le Cesne3, Veridiana Camargo4, Sebastian Bauer5, Sun Young Rha6, Jean-Yves Blay7, David R D'Adamo8, Matthew Guo8 and Robert G Maki9 1Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium 2Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA 3Gustave Roussy, Villejuif,...
Biology and management of clear cell sarcoma: state of the art and future perspectives
Introduction: Clear cell sarcoma (CCS) is an aggressive tumor, typically developing in tendons or aponeuroses. The outcome of this orphan disease is poor, with 5-year and 10-year survival rates of localized CCS around 60–70% and 40–50%. Once the disease has metastasized, it is usually fatal due to its chemotherapy-resistant nature. Systemic treatment options are poorly standardized and the use of chemotherapy is based on weak scientific evidence.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Patrick
Contact Patrick, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack